These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 632139)

  • 1. Combination of radiation and razoxane (ICRF 159) in vivo.
    Hellmann K; Grimshaw MB; Hutchinson GE
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):109-13. PubMed ID: 632139
    [No Abstract]   [Full Text] [Related]  

  • 2. A clinical evaluation of ICRF 159 as a radiosensitising agent.
    Bates T
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):127-31. PubMed ID: 344288
    [No Abstract]   [Full Text] [Related]  

  • 3. Radiotherapy combined with ICRF 159 (NSC 129943).
    Rhomberg WU
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):121-6. PubMed ID: 204615
    [No Abstract]   [Full Text] [Related]  

  • 4. Further evaluation of bimolane and analogs as potential antitumor agents.
    Ren YF; Otter GM; Schmid FA
    Eur J Cancer Clin Oncol; 1985 Apr; 21(4):493-7. PubMed ID: 3859415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of AT1727 on growth and metastasis of murine tumours.
    Li XT; Hutchinson GE; Pym BA; Finch M; Hellmann K
    Eur J Cancer Clin Oncol; 1983 Feb; 19(2):283-7. PubMed ID: 6681774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ICRF-159: current status and clinical prospects.
    Bellet RE; Rozencweig M; Von Hoff DD; Penta JS; Wasserman TH; Muggia FM
    Eur J Cancer (1965); 1977 Nov; 13(11):1293-8. PubMed ID: 590286
    [No Abstract]   [Full Text] [Related]  

  • 7. Radiotherapy and ICRF 159 in the treatment of soft tissue sarcomas.
    Ryall RD
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):133-4. PubMed ID: 632140
    [No Abstract]   [Full Text] [Related]  

  • 8. [The influence of mecytosine on the antiblastic effect of radiation].
    Vershinina SF; Maksimova OV
    Vopr Onkol; 1972; 18(8):80-2. PubMed ID: 4348592
    [No Abstract]   [Full Text] [Related]  

  • 9. ICRF-159 enhancement of radiation response in combined modality therapies. I. Time/dose relationships for tumour response.
    Kovacs CJ; Evans MJ; Schenken LL; Burholt DR
    Br J Cancer; 1979 May; 39(5):516-23. PubMed ID: 486307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double blind controlled clinical trial of radiation plus razoxane (ICRF 159) versus radiation plus placebo in the treatment of head and neck cancer.
    Bakowski MT; Macdonald E; Mould RF; Cawte P; Sloggem J; Barrett A; Dalley V; Newton KA; Westbury G; James SE; Hellmann K
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):115-9. PubMed ID: 344287
    [No Abstract]   [Full Text] [Related]  

  • 11. Letter: Studies of the radiosensitizing action in vivo of 2,2,6,6, tetramethyl-4-piperidinol-N-oxyl (TMPN).
    Hill RP; Fielden EM; Lillicrap SC; Stanley JA
    Int J Radiat Biol Relat Stud Phys Chem Med; 1975 May; 27(5):499-501. PubMed ID: 168164
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of stereoisomers related to ICRF-159 on metastasis of B16 melanoma.
    Zwilling BS; Campolito LB; Reiches NA; George T; Witiak DT
    Br J Cancer; 1981 Oct; 44(4):578-83. PubMed ID: 7295515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ICRF-159 enhancement of radiation response in combined modality therapies. II. Differential responses of tumour and normal tissues.
    Kovacs CJ; Evans MJ; Burholt DR; Schenken LL
    Br J Cancer; 1979 May; 39(5):524-30. PubMed ID: 486308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary report on AT1727 as a potential radiosensitizer.
    Zhang ZY; Liu TF; Zhang XF
    Int J Radiat Oncol Biol Phys; 1984 Dec; 10(12):2305-7. PubMed ID: 6392223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potentiation of combined cis-dichlorodiammineplatinum (II) and irradiation by ICRF-159.
    Kovacs CJ; Schenken LL; Burholt DR
    Int J Radiat Oncol Biol Phys; 1979 Aug; 5(8):1361-4. PubMed ID: 575120
    [No Abstract]   [Full Text] [Related]  

  • 16. ICRF 159, (+/-) 1,2-di(3,5-dioxopiperazin-1-yl) propane NSC-129,943; razoxane.
    Bakowski MT
    Cancer Treat Rev; 1976 Jun; 3(2):95-107. PubMed ID: 821609
    [No Abstract]   [Full Text] [Related]  

  • 17. Enhancement of experimental lung metastases by cultured B16 melanoma cells treated with (+/-)-1,2-bis(3,5-dioxopiperazin-1-y)propane (ICRF-159).
    Lazo JS; Ingber DE; Sartorelli AC
    Cancer Res; 1978 Aug; 38(8):2263-70. PubMed ID: 667822
    [No Abstract]   [Full Text] [Related]  

  • 18. ICRF-187 in clinical oncology.
    Poster DS; Penta JS; Bruno S; Macdonald JS
    Cancer Clin Trials; 1981; 4(2):143-6. PubMed ID: 6788388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiosensitization of pulmonary metastases-I. In vivo testing of hycanthone, insulin and razoxane.
    Davies BM; Watling DC
    Int J Radiat Oncol Biol Phys; 1979 Jun; 5(6):803-9. PubMed ID: 500411
    [No Abstract]   [Full Text] [Related]  

  • 20. Hypoxic cell radiosensitizers and local control by X-ray of a transplanted tumour in mice.
    Sheldon PW; Hill SA
    Br J Cancer; 1977 Jun; 35(6):795-808. PubMed ID: 871367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.